Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The BNT162b2 Pfizer/BioNTech COVID-19 vaccine retains its efficacy against B.1.1.7 in the UK and in reports from Israel.
“Current epidemiological evidence is that the BNT162b2 Pfizer/BioNTech COVID-19 vaccine retains its efficacy against B.1.1.7 in the UK24 and in reports from Israel.28,29”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [28]
Vaccine coverage of 79%, 90%, and 65% was reported in three recent single-centre studies of health-care workers in Israel and the UK.
“three recent single-centre studies in health-care workers in Israel and the UK reported vaccine coverage of 79%, 90%, and 65%, respectively.”
Variability in vaccine effectiveness estimates between studies could result from differences in study design, testing protocols, and study populations.
“Variability in estimates of vaccine effectiveness between studies could result from differences in study design, testing protocols, and study populations”
Current vaccination efforts are resulting in substantial preventive benefits among working-age adults.
“These interim vaccine effectiveness findings for both Pfizer-BioNTech’s and Moderna’s mRNA vaccines in real-world conditions complement and expand upon the vaccine effectiveness estimates from other recent studies (3–5) and demonstrate that current vaccination efforts are resulting in substantial preventive benefits among working-age adults.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Postvaccination COVID-19 among Healthcare Workers, Israel
Amit, S., Beni, S., Biber, A., Grinberg, A., Leshem, E., & Regev‐Yochay, G. (2021) · Emerging infectious diseases · doi:10.3201/eid2704.210016 · Cited by 102 · see citing works
Self-citationWho should be prioritised for COVID-19 vaccines?
Hassan-Smith, Z. K., Hanif, W., & Khunti, K. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32224-8 · Cited by 42 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564 · see citing works
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345 · see citing works
Self-citationLopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389 · see citing works
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831 · see citing works
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 845 · see citing works
Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00790-x · Cited by 767 · see citing works
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706 · see citing works
Bernal, J. L., Andrews, N., Gower, C., Stowe, J., Robertson, C., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · doi:10.1101/2021.03.01.21252652 · Cited by 1,389 · see citing works
“Amit et al estimated a vaccine effectiveness of 85% from 1528 days after the first dose, though they also estimated a 45% reduction from days 1-14 which may indicate that those vaccinated had a lower baseline risk.(31) It is not clear whether this analysis is based on symptom onset date or test date.”
BackgroundGoshen-Lago, T., Waldhorn, I., Holland, R., Szwarcwort-Cohen, M., Reiner-Benaim, A., Shachor-Meyouhas, Y., Hussein, K., Fahoum, L., Baruch, M., Peer, A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2675 · Cited by 147 · see citing works
Mazzoni, A., Di Lauria, N., Maggi, L., Salvati, L., Vanni, A., Capone, M., Lamacchia, G., Mantengoli, E., Spinicci, M., Zammarchi, L., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149150 · Cited by 139 · see citing works
Gilboa, M., Regev-Yochay, G., Mandelboim, M., Indenbaum, V., Asraf, K., Fluss, R., Amit, S., Mendelson, E., Doolman, R., Afek, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31778 · Cited by 128 · see citing works
Self-citationDecreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100150 · Cited by 111 · see citing works
Self-citation
- Authors
- Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Leshem, Eyal
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 397
- Issue
- 10277
- Pages
- 875-877
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7906709
- OpenAlex
- W3133128009
- Cited by
- 306
- References
- 3
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 24 · 2022: 83 · 2021: 179 · 2020: 3
- FWCI
- 23.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- St. George's, University of London
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 pandemic, healthcare workers, vaccine efficacy, breakthrough infection, Israel
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Israel, Medical Staff, Hospital, Retrospective Studies, Infectious Disease Transmission, Patient-to-Professional, Mass Vaccination, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
